Targeted Inhibition of Protein Tyrosine Phosphatase 1B by Viscosol Ameliorates Type 2 Diabetes Pathophysiology and Histology in Diabetic Mouse Model

Aamir Sohail,1 Hajra Fayyaz,1 Hamza Munee1, Idrees Raza,1 Muhammad Ikram1,2 Zia Uddin,2 Sarah Gul3,4 Hailah M. Almohaimeed,4 Ifat Alsharif,5 Fatima S. Alaryani,6 and Imran Ullah1

1Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan
2Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060 KP, Pakistan
3Department of Biological Sciences, FBAS, International Islamic University, Islamabad, Pakistan
4Department of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, P.O.Box 84428, Riyadh 11671, Saudi Arabia
5Department of Biology, Jamoum University College, Umm Al-Qura University, 21955 Makkah, Saudi Arabia
6College of Science, Department of Biology, University of Jeddah, Jeddah, Saudi Arabia

Correspondence should be addressed to Imran Ullah; imranullah@qau.edu.pk

Received 3 February 2022; Accepted 11 July 2022; Published 22 August 2022

1. Introduction

Type 2 diabetes mellitus (T2DM) is one of the most common forms of diabetes. We are living in the middle of a global diabetes epidemic. Emerging pieces of evidence are suggesting the increased expression of protein tyrosine phosphatase 1B (PTP1B) in the pancreas and adipose tissues during T2DM. The negative regulation of the insulin signaling pathway by PTP1B helps the researchers to consider it as a potential therapeutic target for the treatment of insulin resistance and its associated complications. From the literature, we found that compound 5,7-dihydroxy-3,6-dimethoxy-2-(4-methoxy-3-(3-methyl-2-enyl)phenyl)-4H-chromen-4-one (Viscosol) extracted from Dodonaea viscosa can inhibit PTP1B in vitro. Therefore, in this study, we aimed to evaluate the antidiabetic effect of this compound in a high-fat diet (HFD) and low-dose streptozotocin (STZ-) induced T2DM mouse model. For this purpose, T2DM was induced in C57BL/6 male mice by using an already established protocol with minor modification. The compound-treated T2DM mice showed improvements in biochemical parameters, i.e., decrease in the fasting blood glucose level, increased body weight, improved liver profile, and reduction in oxidative stress. Furthermore, to elucidate the inhibition of PTP1B, the expression level of PTP1B was also measured at mRNA and protein levels by real-time PCR and western blot, respectively. Additionally, downstream targets (INSR, IRS1, PI3K, and GLUT4) were examined for confirming the inhibitory effect of PTP1B. Our results suggest that the compound can specifically inhibit PTP1B in vivo and might have the ability to improve insulin resistance and insulin secretion. Based on our experiment, we can confidently state that this compound can be a new PTP1B drug candidate for the treatment of T2DM in the coming future.

2. Material and Methods

The experimental procedures were performed according to the guidelines of the Ethical Review Committee of the University. All the mice were housed in a controlled environment with a 12-hour light/dark cycle. The control and compound-treated mice were fed high-fat diet (HFD) for 12 weeks. The biochemical parameters, i.e., blood glucose level, body weight, and liver profile were measured weekly. For this purpose, the mice were fasted for 12 hours prior to blood collection. The blood glucose level was measured using a glucometer. The liver profile was measured using the standard biochemical kits. The oxidative stress was measured using spectrophotometry. The inhibition of PTP1B was measured by real-time PCR and western blot. The downstream targets were also measured using these techniques.

3. Results

The compound-treated T2DM mice showed improvements in biochemical parameters, i.e., decrease in the fasting blood glucose level, increased body weight, improved liver profile, and reduction in oxidative stress. Furthermore, to elucidate the inhibition of PTP1B, the expression level of PTP1B was also measured at mRNA and protein levels by real-time PCR and western blot, respectively. Additionally, downstream targets (INSR, IRS1, PI3K, and GLUT4) were examined for confirming the inhibitory effect of PTP1B. Our results suggest that the compound can specifically inhibit PTP1B in vivo and might have the ability to improve insulin resistance and insulin secretion. Based on our experiment, we can confidently state that this compound can be a new PTP1B drug candidate for the treatment of T2DM in the coming future.
signaling and secretion [3]. This type of diabetes is also known as non-insulin-dependent diabetes mellitus and is described as the combination of hyperglycemia, insulin deficiency, and insulin resistance [4], and this combinatory condition causes impairment to a number of the systems in the human body, i.e., immune, musculoskeletal, neurological, and vascular. Numerous drugs are available for the treatment of T2DM but have several side effects and implications such as weight gain, cardiovascular problems, hypoglycemia, and gastrointestinal problems. Therefore, there is a need to find a solution for T2DM which would have fewer side effects [5]. The insulin signaling pathway starts as the insulin (INS) binds with the insulin receptors (IR). The autophosphorylation of IR leads to the recruitment of insulin receptor substrate (IRS); further downstream phosphorylation of IRS1/2 results in the activation of the combinatorial possibility of the pathway IR–IRS1/2–PI3K–Akt. Akt is also called Protein Kinase B (PKB). The activation of Akt leads to the translocation of GLUT-4 [6], while the translocation of GLUT4 from the cytoplasm to the plasma membrane handles transferring more glucose inside the cell to minimize the glucose level in blood [7]. Insulin signaling is regulated at several steps as cellular phosphatases are involved in attenuating the insulin signaling by dephosphorylating the insulin receptor which is activated by autophosphorylation [8]. PTP1B, a member of the PTP superfamily, is a major nontransmembrane PTP, encoded by the Ptpn1 gene and ubiquitously expressed in all tissues [9]. PTP1B has a C-terminal hydrophobic region which anchors the protein to the cytoplasmic face of the endoplasmic reticulum and facilitates its ability to substrates. PTP1B inhibits insulin signaling by dephosphorylating the tyrosine residues of IRS-1 and IR-β [10]. The PTP1B is highly expressed in tissues that regulate glucose metabolism, i.e., the heart, skeletal muscles, pancreatic β cells, and liver [11]. In recent years, PTP1B has been the center of focus because of its ability to attenuate the insulin signaling pathway and is currently considered a therapeutic target against diabetes. The negative regulation of insulin metabolism via PTP1B is already demonstrated by using tissue-specific (liver) and whole-body PTP1B knock-out mice. It is well-known that inhibition of PTP1B can reduce insulin insensitivity hence increasing glucose uptake [12, 13]. Dephosphorylation of insulin receptors by PTP1B is reported both in vitro as well as in vivo. Furthermore, an increase in the expression of PTP1B causes insulin resistance

| No. | Primer name | Sequence (5′→3′) | Tm | Amplicon size |
|-----|-------------|------------------|----|---------------|
| 1   | mPdx1-F     | ACTTGAGCGTTCCAATACGG | 60.1 | 85 bp         |
|     | mPdx1-R     | CTTAGCTTGCTCGGCTTC | 60.3 |              |
| 2   | mIrs1-F     | AAGCACTGTGACGAGGCAAGGAA | 60.3 | 72 bp         |
|     | mIrs1-R     | CTTCGTTGACCCGTGTCCTT | 60.4 |              |
| 3   | mGlut4-F    | ACATACCTGACGGGGAAGGGA | 60.1 | 110 bp        |
|     | mGlut4-R    | TGGAGGGGAACAGAAAGTGG | 60.2 |              |
| 4   | mPi3k-F     | GAGACAGGATGGGTCAAGGA | 60.0 | 132 bp        |
|     | mPi3k-R     | CAAAGCAACACGGGAGAAGC | 60.2 |              |
| 5   | mPtpn1-F    | GCATAGGACACAGTGGTAATGCG | 60.5 | 123 bp        |
|     | mPtpn1-R    | AACTCAAGGGAAAAACAGAGG | 60.8 |              |
| 6   | mInsr-F     | CCGTTGAGGGCTAAGCTGTT | 60.7 | 76 bp         |
|     | mInsr-R     | GGTGTAGATGGGTGAGGCC | 60.3 |              |
| 7   | mInsulin-F  | GCCAACAGCAAGGTACGCAAGG | 59.4 | 85 bp         |
|     | mInsulin-R  | CACTAAGGGCTGAGGGTTA | 59.9 |              |
| 8   | mβ-actin-F  | GATCATGCTCTGCTCTGAGGC | 60.0 | 83 bp         |
|     | mβ-actin-R  | ACATCTGCTGAGGGTGAC | 60.0 |              |

**Figure 1:** Mean body weight (g) of all groups of mice versus experimental days. The normal group was only given a standard diet, while STZ-HDF induced and STZ-HFD compound treated were given 5 I.P. STZ injections. Ordinary two-way ANOVA was performed, and results were found significant, ****p < 0.0001.
in the liver, adipose, and muscle tissues [14–16]. Dodonaea viscosa (L). Jacq, a member of the family Sapindaceae grows on rocky and poor soils, is an evergreen shrub. Dodonaea viscosa is centrally originated in Australia and is also distributed in Mexico, Africa, New Zealand, India, Northern Marian Islands, Virginia Islands, Florida, Arizona, South America, and Pakistan [17]. Extracts from the Dodonaea viscosa showed antidiabetic effects in alloxan and streptozotocin-induced diabetes in animal models [18, 19]. In 2010, Veerapur et al. reported the antidiabetic, antioxidant, and hypolipidemic activity of the aerial parts of Dodonaea viscosa in the streptozotocin-induced diabetes rat model [20]. Several studies have confirmed the antimicrobial, anti-inflammatory, antiulcer, smooth muscle relaxant, and wound healing activity of this plant [21]. Rojas et al. screened 294 plants and identified the hypoglycemic activity of Dodonaea viscosa [22]. Dodonaea viscosa is a major source of PTP inhibitors, as revealed by Ziauddin et al. in 2018. They were able to identify a purified polyphenolic compound from aerial parts of the plant which was showing an antidiabetic effect. This potent bioactive compound was isolated as a pale-yellow solid (molecular formula C23H24O7), with a molecular weight of 412.1522. Overall, they have isolated 9 compounds and all compounds have an IC50 value of 13.5–57.9 μM. However, the compound 4, (5,7-dihydroxy-3,6-dimethoxy-2-(4-methoxy-3-(3-methylbut-2-enyl)phenyl)-4H-chromen-4-one), a potent inhibitor of PTP1B has an IC50 value of 13.5 μM and exhibits more fold inhibitory activity than other isolated compounds [23]. It was also inferred from the analysis that this compound works by the mechanism of mixed type 1 inhibition in vitro. In the current study, diabetes was induced by feeding mice with a high-fat diet and carbohydrates resulting in increased plasma insulin levels causing glucose intolerance and insulin resistance. The mice were further followed by a streptozotocin injection causing β cell death and a decrease in β cell mass [24]. Furthermore, we have designed our study to explore the insulin signaling pathway in the presence of compound 4, and the obtained results suggested that the compound was able to block PTP1B. This inhibition also enhances the secretion of insulin and glucose metabolism by increasing the GLUT4 translocation.

2. Materials and Methods

2.1. Animals and Grouping. C57BL/6 mice (25-40 g, 8-12 weeks old), purchased from the National Institute of Health
Animals were maintained in the animal facility of Quaid-i-Azam University according to the guidelines of the National Institute of Health (USA) and the bioethics committee of our university. All protocols for animal handling and experimentation were approved by the Institutional Review Board. The mice were divided into three separate groups ($n=3$ in each group): group 1, control as a positive control; group 2, STZ-HFD-induced diabetic; and group 3, STZ-HFD compound-treated group.

### 2.2. Induction of Diabetes and Compound Treatment

The control group was fed the standard diet (4.1% fat, 22.2% protein, and 12.1% carbohydrates, as a percentage of total kcal) and injected with a single 500 μL injection of saline. For diabetes induction, all the mice fasted for 4-6 hours before the injection of STZ, and blood glucose level (BGL) was estimated by a glucometer (ACCU-CHEK Instant S, Roche Diagnostic, Mannheim, Germany). Diabetes was induced by intraperitoneal injection of streptozotocin (Bio plus Fine Research Chemical, CAT # 41910012-3, Bioworld) for 5 consecutive days at a dose of 40 mg/kg in 500 μL saline. The STZ injected mice were fed on a high-fat diet (HFD, 58% fat, 25% protein, and 17% carbohydrate, as a percentage of total kcal) with 10% glucose solution. On the sixth day, mice were given, and it took around 9-10 days for mice to develop diabetes. Mice with fasting blood glucose levels of $>250$ mg/dL ($>11.1$ mM) were considered diabetic. The BGL was continuously checked by a glucometer until euthanized. In group 3, after the induction of diabetes, HFD was

Figure 5: (a) H&E staining of liver tissue at 10x. Normal control, no significant change was seen in the morphology of the liver. STZ-HFD-induced diabetic mice, representing tissue damage, necrosis at many spots, and lymphocyte infiltration. STZ-HFD compound treated, the image was comparable to the normal with slight inflammatory invasion and tissue regeneration. Here, arrow represents lobular inflammation and cell invasion, star represents hyperaemia, and triangle represents cellular degeneration. (b) The area was selected by using ImageJ, and cells were analyzed. The number of the normal cell was represented in the form of a bar graph. Significant results were found with one-way ANOVA, as $***p = 0.5483$. (c) The inflammatory lobules were represented in the form of a bar graph. Significant results were found with one-way ANOVA, as $***p = 0.3272$. 
removed. On the 11th day, the compound (5,7-dihydroxy-3,6-dimethoxy-2-(4-methoxy-3-(3-methyl but-2-enyl)phenyl)-4H-chromen-4-one) was dissolved in 1% dimethyl sulfoxide (DMSO), and a single intraperitoneal injection (500 μL) was given to mice (33 mg/kg). After the treatment with the compound, the BGL of the mice was continuously checked for 7 days. On the 17th day after BGL estimation, mice were euthanized for further analysis.

2.3. Serum Blood Glucose Analysis. The fasted mice for 4-6 hours were used to check the blood glucose level during the whole study. For output, blood was obtained through the tail vein, and glucose level was checked using a glucometer (ACCU-CHEK Instant S).

2.4. Blood Collection and Serum Separation. At the end of the study, mice were anesthetized, and blood was collected by cardiac puncture with the help of a 23G needle. Serum was separated in 4 mL gel and clot activator vacutainer (Xinle) by centrifuging the tubes at 6000 rpm for 10 min. The supernatant was collected, and sera were stored at -20°C until further use.

2.5. Biochemical Parameters. The antidiabetic effects of the compound in HFD-STZ-induced diabetes in mice were seen. Different biochemical parameters were analyzed. These assays were performed by using enzymatic kits bought from AMP diagnostics. All the procedures and methods performed were according to the given protocol of kits.

2.5.1. Liver Profiling. Liver function biomarkers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), were assayed by using a commercially available liver profiling kit (AMP Diagnostics, Austria).
2.5.2. ROS Assay. For ROS assay, according to Hayashi et al., protocol was followed for estimating the ROS levels in the serum of mice. Hydrogen peroxide was used as the standard solution and incubated at 37°C after 5 min. The working buffer was prepared according to the protocol by adding 100 μL of R1 and R2 buffers. The working buffer was added at a ratio of 1:25 and incubated at 37°C for 1 min. Afterward, absorbance was measured by a multiskan Go, spectrophotometric plate reader (Thermo Fisher Scientific, USA) spectrophotometer at 505 nm. Three readings were recorded.
at 505 nm at an interval of 15 seconds. A calibration curve was constructed by using the concentration of hydrogen peroxide, and, respectively, samples were analyzed according to that [25].

2.6. Histological Analysis by H&E Staining. The liver and pancreas were removed and flushed with PBS and distilled water. The organs were fixed in 10% formalin and kept at room temperature. For histological studies, these organs were then removed, dehydrated, and embedded in the paraffin wax. The fixed tissues were sectioned (4 μm) using a microtome (KD202, China). The tissue sections were stained with hematoxylin and eosin stains. The stained slides were then examined under the bright field microscope (CX41, Olympus Microscope, Japan). ImageJ was used for image analysis and graphical representation of H&E staining.

2.7. RNA Isolation, cDNA Synthesis, and Real-Time qPCR. RNA was extracted from the respective tissues by using the RNA Extraction Kit (PureLink TM, RNA Minikit, Invitrogen by Thermo Fisher Scientific, Cat No # 1218301 8A). Approximately, 30-40 mg of tissue was used for the isolation of total RNA. Isolated RNA (1 μg) was reverse transcribed to cDNA using a high-capacity cDNA synthesis kit (Thermo Fischer Scientific, RevertAid First Strand cDNA Synthesis Kit, USA). The relative abundance of mRNA levels was measured by SYBER Green-based RT-PCR chemistry (Maxima SYBR Green/ROX qPCR Master Mix (2X), Thermo Scientific, USA) using the MyGo Pro PCR system (MyGo PCR systems, IT-IS Life Sciences). Specific primers were used for RT-PCR (Table 1). Each sample was run in triplicates, and β-actin was used as a housekeeping gene. The data were analyzed by the ΔΔCt method, and mRNA fold change was calculated.

2.8. Western Blotting. For western blotting, whole-cell lysate was prepared by using radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris pH 8, 140 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.01% sodium deoxycholate, 1 mM EDTA, 1 mM DTT, 1% protease inhibitor, 1% phosphate inhibitor). Depending upon the size of the tissue (20-30 mg), the 200-300 μL buffer was added to a tube having tissue and was minced. The samples were incubated on ice for 15 minutes.
and vortexed at intermittent intervals of 15 seconds. The samples were additionally incubated on ice for 15 minutes. The whole-cell lysate was centrifuged at 4°C at maximum speed (13000 rpm) for 10 minutes. The supernatant was pipetted out and stored at -20°C for future use. The isolated protein was quantified by Bradford assay using BSA. The concentration of unknown protein samples was figured out from the standard curve by applying the trendline formula of MS Excel. GAPDH was used as a loading control. The data of immunoblotting was analyzed by software (AlphaView SA version 3.4.4.0), and integrated optical density was calculated.

2.9. Statistical Analysis. For statistical analysis, data from at least three replicates were used and analyzed with a one-way, two-way ANOVA, and post hoc Tukey or LSD test using GraphPad Prism (version 9). Microsoft Excel was used for ΔΔCt calculation. A p value of < 0.05 was considered statistically significant. All experiments were performed in triplicates.

3. Results

3.1. Mean Body Weight and Fasting Blood Glucose Level. Bodyweight and blood glucose levels (BGL) were monitored during the experimental period in all three groups. STZ-HFZ compound-treated group showed improvements in body weight as compared to the STZ-HFD-induced diabetic group (diabetic) (Figure 1). In STZ-HFD compound-treated group, a gradual decrease in the BGL was seen after the treatment with a single injection of the compound (Figure 2), while BGL levels in STZ-HFD-induced group remained constantly high.
3.2. Biochemical Parameters. Biochemical testing was performed using the serum. In diabetes, liver damage and alteration in liver enzymes were seen. Hence, liver profiling was performed by analyzing the level of AST, ALT, and ALP enzymes. The level of AST, ALT, and ALP was significantly higher in the STZ-HFD-induced group as compared to normal and STZ-HFD compound treated (Figure 3). Moreover, the compound showed a liver protective effect as the level of AST, ALT, and ALP was comparable to the control group. The absorbance was measured at 340 nm, and analyzed data were represented in the form of a bar graph. Furthermore, ROS level was analyzed in the serum which was found significantly low in the STZ-HFD compound-treated group compared to STZ-HFD-induced group (Figure 4).

3.3. Histological Analysis by H&E Staining. The liver of the STZ-HFD-induced group showed abnormal patterns with lymphocyte infiltration, lobular inflammation, hyperammonemia, and various spots of cytoplasmic degeneration. However, the morphology of the STZ-HFD compound-treated group was like the control group with slight lymphocyte infiltration and liver regeneration (Figure 5(a)). In the case of the liver, the area was selected by using ImageJ, and cells were analyzed. The obtained value was exported to excel for analysis. The selected area obtained from the STZ-HFD-induced and STZ-HFD compound-treated groups was normalized by the control group. The relative number of the normal cell in the liver (Figure 5(b)) and inflammatory lobules in the liver (Figure 5(c)) was represented in the form of a bar graph. Significant results were found with one-way ANOVA, with a p value < 0.0001. In the pancreas, the control and STZ-HFD compound-treated groups showed similar morphology as compared to STZ-HFD-induced group; as the pancreatic morphology was distorted, inflammatory cell invasion and reduction in the β cell mass were seen (Figure 6(a)). In the case of the pancreas, the area was selected by using ImageJ, and cells were analyzed. The obtained value was exported to Excel for analysis. The selected area obtained from the STZ-HFD-induced and STZ-HFD compound-treated groups was normalized by the control group. The relative number of the normal cell in the pancreas (Figure 6(b)) and inflammatory lobules in the pancreas (Figure 6(c)) was represented in the form of a bar graph. Significant results were found with one-way ANOVA, with a p value < 0.0001.

3.4. Correlation of Inhibition of PTP1B in Adipose and Pancreas with the Expression of Downstream Regulators. PTP1B is widely expressed in insulin-sensitive tissues and plays a role as an important negative regulator of insulin signaling. Many studies have reported that inhibition of PTP1B can be considered a therapeutic target in T2DM. Therefore, we further investigated the expression of different downstream components in both tissue (adipose and pancreas) as possibly the inhibition of PTP1B is a contributing factor to insulin signaling. Each cDNA sample was run in triplicates, and GAPDH was used as a housekeeping gene. The data from three independent experiments were analyzed by a ΔΔCt method to calculate the mRNA fold change using normal as a control. The data were represented as means ± SD. The differences between groups were analyzed by two-way ANOVA using Bonferroni post hoc test. A p value of 0.05 was considered statistically significant. Our data showed that the relative abundance of PTPN1 mRNA, the main unit of our study, was decreased in the treated group in both tissues (Figures 7(a) and 8(a)). Moreover, it is known that PTPN1 inhibits the phosphorylation of IR and IRS1. Therefore, inhibition of PTPN1 results in increased expression of IRS1, IRS2, PI3K, and GLUT4 in adipose (Figures 7(b)–7(e)) and INS, IRS1, and PI3K in the pancreas (Figures 8(b)–8(d)) in the compound-treated group as compared to the STZ-HFD diabetic group. Hence, we can conclude that inhibition of PTP1B results in the reduction of mRNA level of PTPN1 which increased downstream regulatory components of insulin signaling. These results show that the compound used during the study can block the activity of PTPN1 at the mRNA level which affects the components of insulin signaling.

3.5. Immunoblotting Showing the Expression of PTP1B and Insulin in Adipose Tissue. To further substantiate the RT-qPCR results, the expression of PTP1B and insulin at the protein level was analyzed by immunoblotting in adipose tissue. The results showed that PTP1B was increased in the adipose tissue of the STZ-HFD-induced group while the reduction in the expression was seen in the compound-treated group (Figure 9(a)). Furthermore, lower expression of insulin was found in the STZ-HFD-induced group, while in the control and compound-treated groups, significant insulin secretion was detected (Figure 9(b)). The immunoblot was analyzed by software (AlphaView SA version 3.4.4.0), and the bar graph is plotted by calculating the integrated optical density (IOD) value by ImageJ. IOD of targets was normalized with GAPDH as an internal control (Figures 9(c)–9(e)). Significant results were found with one-way ANOVA, as *** p = 0.0008.

4. Discussion

Type 2 diabetes mellitus is regarded as resistance to insulin hormone which occurs because of attenuated signaling from the insulin receptors. The global occurrence of T2DM is increasing at an alarming rate. Protein tyrosine phosphatase 1B (PTP1B), a member of PTPase, has been getting intensive attention in research as it takes part in the insulin signaling cascade. The compelling experiments have revealed that PTP1B plays a significant regulatory role in modulating insulin sensitivity, hence, signifying PTP1B as a potential therapeutic target. PTP1B is not only involved in T2DM but also involved in several other diseases, including autoimmune disorders, cardiovascular diseases, cancer, and liver diseases.

Several pieces of evidence from cellular, biochemical, and chemical inhibitor studies have found that PTP1B is a major negative regulator of insulin signaling. Additionally, many studies suggest that the action of insulin can be enhanced by the inhibition of PTP1B. Subsequently, PTP1B has been considered an attractive target for the treatment of
T2DM. In the present study, we tried to analyze the PTP1B inhibitory role of our specific compound extract from Dodonaea viscosa in vivo. Our findings highlight the intriguing fact that inhibition of PTP1B might help to improve insulin resistance and insulin secretion in adipose and pancreatic tissue. Improvements in biochemical parameters such as the decrease in the fasting blood glucose level, increased body weight, and improved liver profile were also seen in our experiment which is consistent with the previously published reports [26]. Histopathological analysis by H&E staining of the liver and pancreas showed comparable results of the STZ-HFD compound-treated and normal groups, while the morphology of liver and pancreas was distorted in the STZ-HFD diabetic group as lymphocyte infiltration, reduced β cell mass, and apoptotic cells were seen. In recent years, in vitro analysis has shown that PTP1B expression can be induced by high glucose, palmitate, fatty acids, and cytokines such as TNF-α and IL-6 [11, 27–29]. The increased level of PTP1B is reported in insulin-sensitive tissues in STZ-induced diabetic mice and rats [30]. In 2012, Vakili et al. reported that inhibiting PTP1B by using shRNA in STZ-induced diabetic mice resulted in a decrease in plasma glucose level [31]. Furthermore, our study also shows a significant reduction in oxidative stress. The elevated level of reactive oxygen species (ROS) in obesity and diabetic individuals has been previously reported [32]. Likewise, in the current study, the level of ROS in the STZ-HFD-induced group was significantly high than in the STZ-HFD compound-treated group which confirms the protective effect of our compound.

It has been previously reported that PTP1B inhibitors increased the IR and IRS1 phosphorylation which results in the increased GLUT4 translocation and glucose uptake in insulin target tissues [33]. Several studies also showed that PTP1B deficient animals enhanced insulin sensitivity, prevented them from weight gain, and increased phosphorylation of IR even if they are fed with an HFD [34]. Likewise, our study also shows that there would be an increased translocation of glucose via GLUT4 which ultimately upregulate the insulin signaling pathway. This phenomenon was confirmed by analyzing the relative mRNA expression of INS, INSR, IRS1, PI3K, GLUT4, and PTPN1. In adipose tissue, we found that the relative mRNA expression of INSR, IRS1, PI3K, and GLUT4 was downregulated in the STZ-HFD diabetic group while upregulated in the STZ-HFD compound-treated group. Furthermore, expression of PTPN1 was significantly decreased in the compound-treated group. Similarly, we have seen an increased expression of INS and IRS1 in the compound-treated group, while downregulation of PTPN1 in pancreatic tissues which were found consistent with the previously reported studies [10].

To substantiate our results, we have confirmed the expression of PTP1B and insulin at the protein level in adipose tissue. We found increased expression of PTPN1 in the STZ-HFD-induced group, while it was inhibited in the compound-treated group. The antidiabetic activity of Dodonaea viscosa (plant extract) is well-known and observed for many years, but a lead compound that can inhibit the PTP1B enzyme was yet not explored. Hence, this assures us that the compound used in the current study can be considered a specific inhibitor of PTP1B.

5. Conclusion

Concluding, we have targeted PTP1B and its downstream targets in the STZ-HFD-induced type II diabetic model via the help of a compound, 5,7-dihydroxy-3,6-dimethoxy-2-(4-methoxy-3-(3-methyl-2-enyl)phenyl)-4H-chromen-4-one, extracted from the Dodonaea viscosa. The antidiabetic and inhibitory potential of this compound on PTP1B has been evaluated in the current study. Collectively, we have investigated the effect of our compound on body weight, histological, and biochemical parameters. Additionally, the study was supported by transcriptomic and proteomic analyses. The data shows a decrease in the level of PTP1B at the mRNA level, and complete inhibition was seen in the compound-treated group. Conclusively, this study will help to develop a new pharmacological drug for the treatment of T2DM specifically by targeting PTP1B.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| IRS          | Insulin receptor substrate |
| STZ          | Streptozotocin |
| PTP1B        | Protein-tyrosine phosphatase 1B |
| TCPTP45      | T cell protein tyrosine phosphatase 45 |
| Akt          | Ak strain transforming |
| T2DM         | Type 2 diabetes mellitus |
| AST          | Serum aspartate aminotransferase |
| ALT          | Serum alanine aminotransferase |
| ALP          | Serum alkaline phosphatase |
| ROS          | Reactive oxygen species |
| b.w          | Bodyweight |
| HFD          | High-fat diet |
| PKB          | Protein kinase B |
| IR           | Insulin receptor |
| DMSO         | Dimethyl sulfoxide |

**Data Availability**

Our data will be available upon the publication of this manuscript.

**Ethical Approval**

All the requirements for this study were fulfilled, and the experiment was done with standard protocols. The study was approved by the Institutional Bioethics Committee of Quaid-i-Azam University, Islamabad.

**Conflicts of Interest**

The authors declare no competing interests.

**Acknowledgments**

This work was supported by the University Research Funding (URF 2019-20) of the Quaid-I-Azam University, Islamabad, Pakistan, and the Princess Nourah Bint Abdulrahman
University Researcher Supporting Project Number PNURSP2022R213, Riyadh, Saudi Arabia.

References

[1] International Diabetes Federation, *IDF Diabetes Atlas*, Brussels, Belgium, 2021.

[2] American Diabetes Association, "Classification and diagnosis of diabetes: standards of medical care in diabetes—2020," *Diabetes Care*, vol. 43, Supplement 1, pp. S14–S31, 2020.

[3] R. A. DeFronzo, E. Ferrannini, L. Gropo et al., "Type 2 diabetes mellitus," *Nature Reviews Disease Primers*, vol. 1, no. 1, pp. 1–22, 2015.

[4] A. B. Olokoba, O. A. Obateru, and L. B. Olokoba, "Type 2 diabetes mellitus: a review of current trends," *Oman Medical Journal*, vol. 27, no. 4, pp. 269–273, 2012.

[5] A. Chaudhury, C. Duvoor, V. S. Reddy Dendi et al., "Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management," *Frontiers in Endocrinology*, vol. 8, p. 6, 2017.

[6] J. M. Lizzano and D. R. Alessi, "The insulin signalling pathway," *Current Biology*, vol. 12, no. 7, pp. R236–R238, 2002.

[7] B. SarathKumar and B. S. Lakshmi, "In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations," *Journal of Molecular Modeling*, vol. 25, no. 9, pp. 1–17, 2019.

[8] E. L. White, Y. Amitai, and M. J. Gutnick, "A comparison of synapses onto the somata of intrinsically bursting and regular spiking neurons in layer V of rat SmI cortex," *Journal of Comparative Neurology*, vol. 342, no. 1, pp. 1–14, 1994.

[9] J. V. Frangioni, P. H. Beahm, V. Shifrin, C. A. Jost, and B. G. Neel, "The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence," *Cell*, vol. 68, no. 3, pp. 545–560, 1992.

[10] F. Gu, D. T. Nguyen, M. Suible et al., "Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress," *Journal of Biological Chemistry*, vol. 279, no. 48, pp. 49689–49693, 2004.

[11] J. M. Zabolotny, Y. B. Kim, L. A. Welsh, E. E. Kershaw, B. G. Neel, and B. B. Kahn, "Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo," *Journal of Biological Chemistry*, vol. 283, no. 21, pp. 14230–14241, 2008.

[12] M. J. Quon, A. J. Butte, and S. I. Taylor, "Insulin signal transduction pathways," *Trends in Endocrinology & Metabolism*, vol. 5, no. 9, pp. 369–376, 1994.

[13] J. Montalivet and B. P. Kennedy, "Therapeutic strategies for targeting PTP1B in diabetes," *Drug Discovery Today: Therapeutic Strategies*, vol. 2, no. 2, pp. 129–135, 2005.

[14] S. S. Dadke, H. C. Li, A. B. Kusari, N. Begum, and J. Kusari, "Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats," *Biochemical and Biophysical Research Communications*, vol. 274, no. 3, pp. 583–589, 2000.

[15] M. Elchelby, P. Payette, E. Michaliszyn et al., "Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene," *Science*, vol. 283, no. 5407, pp. 1544–1548, 1999.

[16] J. M. Zabolotny, F. G. Haj, Y. B. Kim et al., "Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action," *Journal of Biological Chemistry*, vol. 279, no. 23, pp. 24844–24851, 2004.

[17] D. Lawal and I. Yunusa, "Dodonaea viscosa Linn: it’s medicinal, pharmacological and phytochemical properties," *International Journal of Innovation and Applied Studies*, vol. 2, no. 4, pp. 476–482, 2013.

[18] P. Muthukuman, V. Hazeena Begumand, and P. Kalaiarasu, "Anti-diabetic activity of Dodonaea viscosa (L) leaf extracts," *International Journal of PharmTech Research*, vol. 3, pp. 136–139, 2011.

[19] World Health Organization, *WHO Traditional Medicine Strategy: 2014-2023*, World Health Organization, 2013.

[20] V. P. Veerapur, K. R. Prabhakar, V. K. Parihar et al., "Antidiabetic, hypolipidaemic and antioxidant activity of Dodonaea viscosa aerial parts in streptozotocin-induced diabetic rats," *International Journal of Phytomedicine*, vol. 2, no. 1, 2010.

[21] M. Getic, T. Gebre-Mariam, R. Rietz et al., "Evaluation of the anti-microbial and anti-inflammatory activities of the medicinal plants Dodonaea viscosa, Rumex nervosus and Rumex abyssinicus," *Fitoterapia*, vol. 74, no. 1–2, pp. 139–143, 2003.

[22] A. Rojas, S. Cruz, H. Ponce-Monter, and R. Mata, "Smooth muscle relaxing compounds from Dodonaea viscosa, 5* Planta Medica*, vol. 62, no. 2, pp. 154–159, 1996.

[23] Z. Uddin, Y. H. Song, M. Ullah, Z. Li, J. Y. Kim, and K. H. Park, "Isolation and characterization of protein tyrosine phosphatase 1B (PTP1B) inhibitory polyphenolic compounds from Dodonaea viscosa and their kinetic analysis," *Chemistry*, vol. 6, p. 40, 2018.

[24] S. Lenzen, "The mechanisms of alloxan-and streptozotocin-induced diabetes," *Diabetologia*, vol. 51, no. 2, pp. 216–226, 2008.

[25] I. Hayashi, Y. Morishita, K. Imai, M. Nakamura, K. Nakachi, and T. Hayashi, "High-throughput spectrophotometric assay of reactive oxygen species in serum," *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, vol. 631, no. 1, pp. 55–61, 2007.

[26] D. H. Kim, S. Lee, Y. W. Chung et al., "Antiobesity and antidiabetic effects of a Cordyceps sinensis hydrophilic extract presenting PTP1B inhibitory potential," *BioMed Research International*, vol. 2016, Article ID 8432759, 11 pages, 2016.

[27] M. Delibegovic, D. Zimmer, C. Kaufman et al., "Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress, *Diabetes*, vol. 58, no. 3, pp. 590–599, 2009.

[28] J. Wu, L.-J. Yang, and D.-J. Zou, "Rosiglitazone attenuates tumor necrosis factor-a-induced protein-tyrosine phosphatase-1B production in HepG2 cells," *Journal of Endocrinological Investigation*, vol. 35, no. 1, pp. 28–34, 2012.

[29] L. Parvaneh, R. Meshkani, S. Bakhhtiyari et al., "Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells*, *Biochemical and Biophysical Research Communications*, vol. 396, no. 2, pp. 467–471, 2010.

[30] K. Adeli, J. Macri, A. Mohammadi, M. Kito, R. Urade, and D. Cavallo, "Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells," *Journal of Biological Chemistry*, vol. 272, no. 36, pp. 22489–22494, 1997.

[31] S. Vakili, S. S. S. Ebrahimi, A. Sadeghi et al., "Hydrodynamic-based delivery of PTP1B shRNA reduces plasma glucose levels..."
in diabetic mice,” *Molecular Medicine Reports*, vol. 7, no. 1, pp. 211–216, 2013.

[32] X.-H. Wang, K.-X. Zhu, J.-Y. Li, C. Lei, and A.-J. Hou, “Vistri-terpenoids A and B, two new 24-nor-oleanane triterpenoids from Dodonaea viscosa,” *Chemistry & Biodiversity*, vol. 15, no. 11, article e1800426, 2018.

[33] K. Egawa, H. Maegawa, S. Shimizu et al., “Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells,” *Journal of Biological Chemistry*, vol. 276, no. 13, pp. 10207–10211, 2001.

[34] S. Koren and I. George Fantus, “Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus,” *Best Practice & Research Clinical Endocrinology & Metabolism*, vol. 21, no. 4, pp. 621–640, 2007.